港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

719.918

+3.9520.55%

漲家數：15

跌家數：15

平家數：4

市盈率：- -

高：728.504

開：715.966

低：704.159

收：715.966

成交量：1.03億

成交額：37.60億

市值：4,603.13億

流通市值：4,086.12億

資料載入中...

總覽新聞資訊

諾誠健華（688428）披露證券變動月報表，4月3日股價下跌1.9%

海南海藥擬減持中國抗體股份數量不超過6800萬股

深度觀察｜從「燒錢」走向「賺錢」，2025年中國創新藥上市公司收入突破1000億元，我們離全球「領跑」還差多遠?

每日经济新闻

海南海藥擬減持中國抗體不超5%股份

醫藥賽道領升，港股通創新藥ETF易方達（159316）本周成交放量

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=13"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":719.91754,"timestamp":1776413292136,"preClose":715.96594,"halted":0,"volume":103129317,"delay":0,"changeRate":0.005519,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":3.951599,"latestTime":"04-17 16:00:00","open":715.96594,"high":728.5041,"low":704.15936,"amount":3759884233,"amplitude":0.034003,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"pbRate":5.627353,"peRate":-94.073273,"turnoverRate":0.00368,"increases":14,"decrements":17,"flats":2,"marketCap":460313417856,"floatMarketCap":408611897616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":728.5041,"amplitude":0.034003,"preClose":715.96594,"low":704.15936,"pbRate":"5.627353","latestPrice":719.91754,"volume":103129317,"delay":0,"open":715.96594,"prevYearClose":556.26263,"prevWeekClose":666.249,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":666.249,"twentyDayClose":575.488,"sixtyDayClose":612.872,"secType":"PLATE","market":"HK","turnoverRate":0.00368,"peRate":-94.073273,"marketCap":460313417856,"floatMarketCap":408611897616,"timestamp":1776413292136,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":15,"down":15,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:13,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624566806","title":"諾誠健華（688428）披露證券變動月報表，4月3日股價下跌1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624566806","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624566806?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 22:12","pubTimestamp":1775225533,"startTime":"0","endTime":"0","summary":"近日，诺诚健华发布港股公告《证券变动月报表》。公告显示，截至2026年3月31日，公司法定注册资本无变动，已发行股份总数与上月底结存一致，无增减。此外，2023年及2024年人民币股股权激励计划项下部分限制性股票失效，但本月未因协议安排导致股份增减。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32125629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK0239","09969","161027","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624016650","title":"海南海藥擬減持中國抗體股份數量不超過6800萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624016650","media":"北京商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624016650?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 21:14","pubTimestamp":1775222054,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）4月3日晚间，海南海药（000566）发布公告称，公司拟通过集中竞价交易及大宗交易的方式减持公司目前持有的中国抗体制药有限公司（HK03681，以下简称“中国抗体”）股份数量不超过6800万股（占其总股本的比例不超过5%）。公告显示，中国抗体系公司参股企业，海南海药持有中国抗体15888.21万股股份，占其总股本的11.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695195266.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695195266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","000566","BK1574","BK0188","BK0070","BK0060","03681","BK0146","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502586","title":"深度觀察｜從「燒錢」走向「賺錢」，2025年中國創新藥上市公司收入突破1000億元，我們離全球「領跑」還差多遠?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502586","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502586?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 21:06","pubTimestamp":1775221600,"startTime":"0","endTime":"0","summary":"随着2025年各家上市公司年报密集出炉，中国创新药产业的结构性变革，正式浮出水面。《每日经济新闻》记者不完全统计，百济神州、信达生物、华领医药、诺诚健华、乐普生物、荣昌生物、迈博药业、北海康成等公司扭亏为盈。创新药企终于从“烧钱”走向“赚钱”，与此同时，中国已跃升为全球创新药优质在研管线的核心供给地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695191747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695191747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500126","title":"海南海藥擬減持中國抗體不超5%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500126","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624500126?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 20:57","pubTimestamp":1775221020,"startTime":"0","endTime":"0","summary":"4月3日，海南海药（000566）发布公告，公司拟通过集中竞价交易及大宗交易的方式减持中国抗体（03681）股份数量不超过6800万股，不超过公司总股本的5%。截至公告披露日前一交易日，公司持有中国抗体1.59亿股股票资产的市值约为2.8亿港元，此次交易旨在优化公司资产结构，提高资产流动性及使用效率。2025年前三季度，海南海药实现收入6.40亿元，归母净利润-2.42亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695191451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1574","BK0070","BK0060","000566","BK1161","03681","BK0146","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624573726","title":"醫藥賽道領升，港股通創新藥ETF易方達（159316）本周成交放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2624573726","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624573726?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 19:53","pubTimestamp":1775217203,"startTime":"0","endTime":"0","summary":"本周，医药赛道领涨，指数层面，恒生港股通创新药指数上涨9.6%，中证港股通医药卫生综合指数上涨7.5%，中证创新药产业指数上涨4.2%，中证生物科技主题指数上涨2.5%，沪深300医药卫生指数上涨1.2%，港股通创新药ETF易方达(159316，联接基金A/C：024328/024329)本周成交额超50亿元，较上周大幅放量。国信证券指出，政府工作报告首次将生物医药定位为新兴支柱产业，并明确 “十五五” 期间将实施产业创新工程，推动生物医药成为新质生产力的重要引擎。同时，创新药出海合作持续深化，中国创新药研发能力获跨国药企认可，BD交易爆发式增长，商业化前景持续向好。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/03/20260403715725.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/03/20260403715725.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32125422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09939","BK1574","159316","BK1515","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":13,"totalSize":245,"code":"91000000","status":"200"}]}}